EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieÄquivalenzstudieOpen Access · CC BY-NC 4.0

Cost‐effectiveness analysis of once‐daily insulin glargine 300 U/mL versus insulin degludec 100 U/mL using the BRAVO diabetes model

Hui Shao, Lizheng Shi, Vivian Fonseca, Abdul Jabbar Omar Alsaleh, Jasvinder Gill, Charlie Nicholls

Diabetic Medicine · 2023

DOI: 10.1111/dme.15112 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetic Medicine, 2023. Verfasst von Hui Shao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hubert Department of Global Health, Emory Rollins School of Public Health, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Diabetes UK, Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

A cost‐effectiveness analysis was conducted to compare insulin glargine 300 U/mL (Gla‐300) versus insulin degludec 100 U/mL (IDeg‐100) in insulin‐naïve adults with type 2 diabetes (T2D) sub‐optimally controlled with oral anti‐diabetic drugs (OADs).

Methods

The BRAVO diabetes model was used to assess costs and outcomes for once‐daily Gla‐300 versus once‐daily IDeg‐100 from a US healthcare sector perspective. Baseline clinical data were based on BRIGHT, a 24‐week, non‐inferiority, randomised control trial comparing Gla‐300 and IDeg‐100 in adults with T2D sub‐optimally controlled with OADs (with or without glucagon‐like peptide‐1 receptor agonists). Treatment costs were based on doses observed in BRIGHT as well as net prices. Costs associated with complications were based on published literature. Lifetime costs (US$) and quality‐adjusted life‐years (QALYs) were predicted and used to calculate incremental cost‐effectiveness ratio estimates; extensive scenario and sensitivity analyses were conducted.

Results

Overall lifetime medical costs were estimated to be $327,904 and $330,154 for people receiving Gla‐300 and IDeg‐100, respectively; insulin costs were $43,477 and $44,367, respectively. People receiving Gla‐300 gained 8.024 QALYs and 18.55 life‐years, while people receiving IDeg‐100 gained 7.997 QALYs and 18.52 life‐years. Because Gla‐300 was associated with a cost‐saving of $2250 and 0.027 additional QALYs, it was considered to be dominant compared with IDeg‐100. Results of the scenario and sensitivity analyses confirmed the robustness of the base case results.

Conclusion

Gla‐300 was the dominant treatment option compared with IDeg‐100 based on the willingness‐to‐pay threshold of $50,000/QALY. Results remained robust against a wide range of alternative assumptions on key parameters.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2AdultHumansInsulin GlargineHypoglycemic AgentsCost-Effectiveness AnalysisCost-Benefit AnalysisInsulinInsulin, Long-ActingNitriles

Stichwörter der Autor:innen

costs and cost analysisdiabetes mellitus type 2insulin degludecinsulin glargine

Substanzen

Insulin GlargineHypoglycemic AgentsInsulininsulin degludecInsulin, Long-ActingtetrachloroisophthalonitrileNitriles

Autor:innen und Institutionen

  • Hubert Department of Global Health, Emory Rollins School of Public Health, Atlanta, Georgia, USA.
  • Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA.
  • School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA.
  • School of Medicine, Tulane University, New Orleans, Louisiana, USA.
  • Sanofi, Milan, Italy.
  • Sanofi, Bridgewater, New Jersey, USA.

Förderung

  • Diabetes UK
  • Sanofi

Zitieren

APA

Shao, H., Shi, L., Fonseca, V., Alsaleh, A. J. O., Gill, J., & Nicholls, C. (2023). Cost‐effectiveness analysis of once‐daily insulin glargine 300 U/mL versus insulin degludec 100 U/mL using the BRAVO diabetes model. Diabetic Medicine. https://doi.org/10.1111/dme.15112

Vancouver

Shao H, Shi L, Fonseca V, Alsaleh AJO, Gill J, Nicholls C. Cost‐effectiveness analysis of once‐daily insulin glargine 300 U/mL versus insulin degludec 100 U/mL using the BRAVO diabetes model. Diabetic Medicine. 2023. doi:10.1111/dme.15112

BibTeX
@article{Shao2023,
  author = {Shao, Hui and Shi, Lizheng and Fonseca, Vivian and Alsaleh, Abdul Jabbar Omar and Gill, Jasvinder and Nicholls, Charlie},
  title = {Cost‐effectiveness analysis of once‐daily insulin glargine 300 U/mL versus insulin degludec 100 U/mL using the BRAVO diabetes model},
  journal = {Diabetic Medicine},
  year = {2023},
  doi = {10.1111/dme.15112}
}
Kostenlos starten →